Page 51 - Read Online

Page 14 of 14 Tosato et al. J Cancer Metastasis Treat 2021;7:52 https://dx.doi.org/10.20517/2394-4722.2021.120

85. Schliemann C, Bieker R, Thoennissen N, et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia.
Leukemia 2007;21:1901-6. DOI PubMed
86. Rouault-Pierre K, Lopez-Onieva L, Foster K, et al. HIF-2α protects human hematopoietic stem/progenitors and acute myeloid
leukemic cells from apoptosis induced by endoplasmic reticulum stress. Cell Stem Cell 2013;13:549-63. DOI PubMed
87. Velasco-Hernandez T, Hyrenius-Wittsten A, Rehn M, Bryder D, Cammenga J. HIF-1α can act as a tumor suppressor gene in murine
acute myeloid leukemia. Blood 2014;124:3597-607. DOI PubMed
88. Vukovic M, Guitart AV, Sepulveda C, et al. Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for
disease maintenance. J Exp Med 2015;212:2223-34. DOI PubMed PMC
89. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic
malignancies. Cancer Res 1999;59:728-33. PubMed
90. Hassan HT, Zander A. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta
Haematol 1996;95:257-62. DOI PubMed
91. Poulos MG, Gars EJ, Gutkin MC, et al. Activation of the vascular niche supports leukemic progression and resistance to
chemotherapy. Exp Hematol 2014;42:976-986.e3. DOI PubMed PMC
92. Ossenkoppele GJ, Breems DA, Stuessi G, et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group
for Clinical Cancer Research (SAKK). Lenalidomide added to standard intensive treatment for older patients with AML and high-risk
MDS. Leukemia 2020;34:1751-9. DOI PubMed
93. Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML.
Nat Biotechnol 2010;28:275-80. DOI PubMed PMC
94. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or
refractory acute myeloid leukemia. Blood 2012;119:3917-24. DOI PubMed PMC
95. Abraham M, Klein S, Bulvik B, et al. The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK,
BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Leukemia 2017;31:2336-46. DOI PubMed
96. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med
2006;12:1167-74. DOI PubMed
97. Jacamo R, Chen Y, Wang Z, et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates
chemoresistance. Blood 2014;123:2691-702. DOI PubMed PMC
98. Kannan S, Sutphin RM, Hall MG, et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp
Med 2013;210:321-37. DOI PubMed PMC
99. Laranjeira AB, Yang SX. Therapeutic target discovery and drug development in cancer stem cells for leukemia and lymphoma: from
bench to the clinic. Expert Opin Drug Discov 2016;11:1071-80. DOI PubMed
100. Granados-Principal S, Liu Y, Guevara ML, et al. Inhibition of iNOS as a novel effective targeted therapy against triple-negative
breast cancer. Breast Cancer Res 2015;17:25. DOI PubMed PMC
101. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous
leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res
2004;10:3577-85. DOI PubMed
102. Ossenkoppele GJ, Stussi G, Maertens J, et al. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a
randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for
Clinical Cancer Research (SAKK). Blood 2012;120:4706-11. DOI PubMed
103. Müller A, Lange K, Gaiser T, et al. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with
myeloid leukemia. Leuk Res 2002;26:163-8. DOI PubMed
104. Reikvam H, Hatfield KJ, Lassalle P, Kittang AO, Ersvaer E, Bruserud Ø. Targeting the angiopoietin (Ang)/Tie-2 pathway in the
crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and
inhibition of constitutive agonistic Ang-1 release. Expert Opin Investig Drugs 2010;19:169-83. DOI PubMed
105. Lane SW, Wang YJ, Lo Celso C, et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood
2011;118:2849-56. DOI PubMed PMC